MPL Overexpression Induces a High Level of Mutant-Calr/MPL Complex: A Novel Mechanism of Ruxolitinib Resistance in Myeloproliferative Neoplasms with Calr Mutations

【Introduction】 Although Ruxolitinib (RUX), a JAK1/2-inhibitor, is an effective treatment option for primary myelofibrosis, tumor cells become resistant to this drug in many MPN patients, causing poor prognosis of MPN patients. Until now, various studies have elucidated the mechanisms of RUX-resistan...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.16-17
Hauptverfasser:	Yasuda, Shunichiro, Aoyama, Satoru, Yoshimoto, Ryoto, Watanabe, Daisuke, Akiyama, Hiroki, Yamamoto, Kouhei, Fujiwara, Takeo, Sakaida, Emiko, Edahiro, Yoko, Imai, Misa, Araki, Marito, Komatsu, Norio, Kawamata, Norihiko
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!